• RJDG acquires and manages assets in three diverse markets: construction, digital healthcare services, and environmental solutions
• Asset portfolio includes Silex Interiors, ioSoft Inc., and Earthlinc Environmental Solutions
• Silex Interiors manufactures, distributes, and installs bathroom and kitchen furniture, countertops, and related products; awarded contract that is expected to generate $850,000+ revenue in 2023
• ioSoft Inc. provides secure payment technologies, cloud-based software, and professional services to healthcare industry; recently procured software development and IT support contract to customize ioSoft Suites for the RailPro Group
• Earthlinc Environmental Solutions offers patented waste processing technology for commercial chicken and hog farms; transforms waste into animal feed while recycling the water for reuse on the farm

Diversification is critical to investment success for many reasons: stable returns, risk reduction, and protection against market volatility. With these principles in mind, RJD Green (OTC: RJDG) a holding company, manages assets in three diverse, high-growth industries in separate “recession-resistant” markets, including construction, digital healthcare services, and environmental solutions.

RJDG formed its specialty construction division to focus on industrial contracting, building material products, and construction services. The company’s first acquisition, Silex Interiors, is a manufacturer, distributor, and installer of countertops, cabinets, and related bathroom and kitchen products with a large target market comprising commercial contractors, residential builders, new and renovation contractors, and retail customers. With the aim of filling a market niche between “big box” stores and smaller retail distributors, RJDG plans to launch Silex into major national markets through internal expansion, franchising, and supplementary acquisitions.

Silex was awarded a large contract for natural stone countertops and cabinets in May 2023 that is expected to generate over $850,000 in revenue (https://ibn.fm/olu6H). “This significant commercial contract awarded to Silex continues the revenue progression in our commercial business segment and reflects geographic expansion,” said RJD Green CEO Ron Brewer. “The commercial contracts have helped offset the traditional seasonal revenue downturn that occurs in our home building sector and will contribute to revenue growth for the remainder of the year. These results reflect our continued implementation of our growth plan for Silex Holdings to expand market segments and broaden our customer base.”

ioSoft Inc., a software company under RJDG’s software division, provides secure payment technologies, cloud-based software, and professional services to healthcare payers and providers. The company’s SaaS offerings integrate seamlessly with legacy or existing systems, offering clients a flexible, scalable, cloud-based solution for managing medical billing, healthcare claims adjudication, and electronic payments.

RJD Green recently announced that ioSoft procured a software development and IT support contract for the RailPro Group, a consulting and marketing team focused on retail marketing and energy-related companies (https://ibn.fm/j7bNy). Under the agreement, ioSoft will customize the ioSoft Suite’s platform, including its ioSoft Unified Payment System(TM) and ioSoft LinkUp(TM) – a robust communication interface enabling users to view claim information, update enrollment, and access ID cards 24/7 from any connected device.

Earthlinc Environmental Solutions, part of RJDG’s environmental services division, provides North American companies with green solutions to ecological challenges. The company’s first acquisition, Animal Waste Management, offers patented waste processing technology for commercial chicken and hog farms. Developed with support from the University of Arkansas and the Missouri Department of Natural Resources, the technology transforms liquid, solid, and gas waste into clean, odorless, bacteria-free animal feed while recycling the water to be reused on the farm.

Based in Tulsa, Oklahoma, RJD Green Inc.’s management team leverages a successful track record in the public and private sectors, with extensive experience in each area of focus under its diverse divisions. The team expertly matches investments with projects to optimize growth, profitability, and shareholder returns.

For more information, visit the company’s website at www.RJDGreen.com.

NOTE TO INVESTORS: The latest news and updates relating to RJDG are available in the company’s newsroom at https://ibn.fm/RJDG

• D-Wave’s quantum solutions help businesses solve computationally complex optimization problems, including logistics, employee scheduling, factory processes, and more
• Advantage(TM) is D-Wave’s fifth-generation quantum computer featuring industry-leading 5,000+ qubits and 15-way qubit connectivity
• D-Wave’s commercial customers include blue-chip industry leaders like Mastercard, Deloitte, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., and Lockheed Martin

Business leaders today are faced with a myriad of solutions to consider for integration into their organization’s IT infrastructure, many of which are critical in achieving meaningful operational efficiency and business advantage. One of the most promising yet perplexing solutions is quantum computing. Most businesses are faced with a vast array of optimization problems, but solving those challenges efficiently can be incredibly challenging. D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, focuses on solving such challenges by delivering value to customers through practical quantum solutions for problems such as logistics, artificial intelligence, drug discovery, scheduling, and financial modeling.

As a leader in quantum computing, D-Wave has delivered the world’s first commercial quantum computer, the first real-time quantum cloud service, countless highly proprietary hardware and software products, and numerous scientific milestones. These innovations serve to help organizations harness the power of quantum technology to address their most computationally complex problems and to help business leaders recognize when to consider quantum over classical computing to tackle their biggest challenges.

Classical computers offer limited computation – using bits represented by 0s and 1s to store information. Quantum computers use quantum bits (qubits) to encode information as 0s and 1s with the ability to use them simultaneously. This superposition, along with other quantum mechanical phenomena and tunneling, enables quantum computers to manipulate enormous combinations all at once.

When using classical computers, business leaders are faced with the inability to search multiple avenues for solutions to complex problems – the solutions are often time-consuming and may never come to fruition. D-Wave’s quantum computer uses quantum annealing to search for solutions to these problems, with the goal of ultimately finding the best solutions without waiting weeks or months for an answer.

D-Wave’s current commercial quantum product offerings include:

• Advantage – a fifth-generation quantum computer featuring 15-way qubit connections and processor architecture with more than 5,000 qubits.
• Leap(TM) – the company’s quantum cloud service that allows developers proficient in Python to begin building and running quantum applications. Leap delivers immediate, real-time access to D-Wave’s Advantage quantum computer and hybrid solver services, with enterprise-class performance and scalability.
• Ocean(TM) – a suite of open-source Python tools that empower developers to experiment, rapidly develop, and harness the power of Advantage to solve complex problems.
• Launch(TM) – an onboarding solution that helps businesses get started on the quantum journey. Launch was designed to guide enterprises from problem discovery through in-production application deployment.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO and Lockheed Martin. D-Wave features a diverse and robust collection of use cases on its Customer Success Stories page, showing how quantum computing has provided value in the real world (https://ibn.fm/ecL2y).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

• About 125 million people worldwide have psoriasis, a chronic disease where the immune system becomes overactive, causing skin cells to multiply too quickly
• The psoriasis treatment market is expected to reach $48.33 billion by 2030, driven by an increase in diagnosed patients and the prevalence of skin disorders in developed nations
• Scinai’s NanoAbs targeting the IL-17 family of cytokines, which have shown promise in treating psoriasis, may offer significant advantages over Apogee Therapeutics, whose recent IPO has resulted in a $1 billion market cap
• Scinai’s NanoAbs offer additional routes of administration, a higher affinity and binding to the target, and stability at room temperature – key differentiators to currently available treatments on the market today

Psoriasis is a chronic disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis. Nearly 50% of people with psoriasis experience moderate to severe symptoms (https://ibn.fm/jgqwh). The psoriasis treatment market was valued at $16.45 billion in 2022 and is expected to grow at a CAGR of 7.8%, reaching $48.33 billion by 2030. The market’s growth is attributed to the number of patients diagnosed with psoriasis and an increasing prevalence of skin disorders in developed nations (https://ibn.fm/0rr6U).

Antibodies and nanobodies against the IL-17 (Interleukin-17) cytokine and other family cytokines are showing success in the treatment of psoriasis and associated immune diseases. Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, in collaboration with Max Planck Society and the University Medical Center Gottingen, has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 as treatments for all potential indications, starting with psoriasis and psoriatic arthritis.

In addition to Scinai, Apogee Therapeutics (NASDAQ: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunological indications, is also targeting IL-17 for psoriasis treatment. Apogee went public in July 2023 at $500 million pre-money, raising $300 million in an upsized deal, and now exceeds a $1 billion market cap.

Both companies are currently in the pre-clinical stage of development – but Scinai believes that its NanoAbs exhibit multiple advantages over Apogee’s product, including:

• Being amenable to new routes of administration – including inhalation and intradermal injection, neither of which work with regular antibodies. Scinai’s NanoAbs potentially create a new market opportunity that does not directly compete with other companies with existing antibody treatments by targeting the large, underserved population of patients with mild to moderate psoriasis.
• Higher affinity and better binding suggest that Scinai’s NanoAbs may permit lower dosages with fewer side effects by providing a higher affinity and better binding to the target, lowering the costs associated with treatment.
• Stability at room temperature – Regular antibodies require complex cold chain logistics until administered to the patient. These treatments are more expensive and limit where and when treatment can be administered, leading to high spoilage. Scinai’s NanoAbs are stable at room temperature, expanding the opportunity for administration and reducing spoilage.

Scinai’s alpaca-derived NanoAbs offer a significant advantage to the underserved population, especially those with mild to moderate psoriasis. Its product potentially offers advantages that Apogee’s product cannot and significantly enhances the route of administration, binding to the target, and an increased window of administration.

The company’s leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb. It has built, owns, and operates a 20,000-square-foot state-of-the-art GMP biologics manufacturing facility that houses laboratories, production facilities, and offices, giving the company a unique advantage in the industry.

For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

• Lexaria Bioscience has completed several studies that confirm and support the superiority and advantages of its patented DehydraTECH(TM) technology over traditional oral delivery methods
• The company recently announced results from its human oral nicotine study NIC-H22-1 comparing its DehydraTECH-nicotine pouch to world-leading brands, Zyn(R) and on!(R)
• Results from the study demonstrated that DehydraTECH-nicotine was statistically significantly faster in reaching Tmax than both brands
• Lexaria has also undertaken other investigational research programs, including the analysis and execution of hypertension, diabetes, hormone therapy, and dementia studies, which could birth excellent partnership opportunities, supporting further growth
• A report by Zacks Investment Research discussed the nicotine study alongside Lexaria’s other recent milestones, maintaining a $12.00 price target

Lexaria Bioscience (NASDAQ: LEXX), a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform, continues to devote an increasing proportion of its resources and focus toward research and development (“R&D”) as part of its overall goal to establish areas of investigation for commercial pursuits and reduce risks of the unknown for both commercial and regulatory goals.

In the three months ended May 31, 2023 (“Q3 2023”), for example, the company increased its R&D expenses 118% year over year to $1.64 million in Q3 2023 from $752,095 in Q3 2022, with a recent Zacks Investment Research report attributing this expenditure to Lexaria’s multiple DehydraTECH investigational research programs then underway, including analysis and execution of hypertension, nicotine, and diabetes studies (https://ibn.fm/vy8qj). The report also lauded the company’s efficient use of capital, which allowed its R&D activities to expand into new preclinical work, including hormone therapy and dementia.

“While still at an early stage, these programs could be excellent partnership opportunities that will support further growth and potentially provide growth capital,” reads the report (https://ibn.fm/0L40v). “Research efforts around these indications help further characterize DehydraTECH-CBD and its advantages compared with traditional delivery methods.”

The company has completed several studies confirming and supporting DehydraTECH’s superiority and advantages over traditional oral delivery methods. One such study, the human nicotine study NIC-H22-1, compared its DehydraTECH-processed nicotine tobacco-free pouch to two oral nicotine pouch brands, Zyn(R) (from Swedish Match) and on!(R) (from Helix Innovations LLC, a subsidiary of Altria Group Inc.) The randomized, double-blinded, crossover study involved 36 subjects, each dosed three times over several weeks. In May, the company announced that the dosing of the 36 patients was completed and, in early August, issued a press release announcing topline results.

Results from the study demonstrated a statistically significant difference between the time taken to achieve maximum blood saturation levels (“Tmax”) for DehydraTECH-nicotine and both Zyn and on! “Time to Tmax of 15.37 minutes was 2.3 minutes faster than what was produced in the on! arm and 3.1 minutes faster than the time measured in the Zyn arm. In percentage terms, this represented a 15% and 20% faster response to achieve maximum blood saturation levels,” summarizes the report.

Lexaria also used as a benchmark the Tmax to be reached with a combustible cigarette, citing a pharmacokinetic study that put the figure at 8 minutes. “Relative to this benchmark, the company put together a comparison of other nicotine delivery methods, including the data generated from the NIC-H22-1 study. Of the eight comparable vehicles, DehydraTECH oral pouch was the fastest to Tmax relative to combustible cigarettes,” the report continues.

The study also evaluated qualitative aspects of DehydraTECH-nicotine, reporting its superiority across six different categories that examined the desirable and undesirable attributes of nicotine consumption. The categories included euphoria and head rush, tolerability, pleasure, mouth and throat burn, nausea, and hiccups. With these positive results in hand, Zacks expects that partner work with global tobacco juggernauts will expand.

“Within just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world’s leading existing brands,” commented Lexaria CEO Chris Bunka in an August 9 press release (https://ibn.fm/NS89s). “This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths.”

Zacks’ report also covered Lexaria’s other recent milestones, including the move to incorporate a new wholly owned subsidiary called Lexaria Nutraceutical Corp. The move is intended to optimize the company’s strategy, helping maximize the potential for its DehydraTECH technology in multiple markets worldwide. Moreover, the report discussed Lexaria’s recent publications, patents, and capital raise, as well as details from its hypertension and diabetes studies.

With the recently released nicotine data preparing Lexaria to enter into discussions with prospective partners and its hypertension program on course to result in an Investigational New Drug (“IND”) application, Zacks maintains a price target of $12.00 per share.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Shoals Technologies Group (NYSE: SHLS) is a leading provider of electrical balance of systems (“EBOS”) solutions for solar, storage, and electric vehicle charging infrastructure. Since its founding in 1996, the company has introduced innovative technologies and systems solutions that allow its customers to substantially increase installation efficiency and safety while improving system performance and reliability. Shoals Technologies Group, Inc. is a recognized leader in the renewable energy industry whose solutions are deployed on over 62 GW of solar systems globally. For more information, visit the company’s website at www.Shoals.com.

To schedule a one-on-one meeting, please contact your ROTH MKM representative.

To view IBN’s coverage of the conference, visit https://ibn.fm/RothSolar2023

About IBN’s Coverage

IBN, a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the companies participating at 10th Annual Solar & Storage Symposium. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• SuperCom has introduced the all-in-one PureOne monitoring device with three unique tech modules, offering advanced technology for the cost-effective electronic home and civil monitoring of offenders
• The electronic offender monitoring market in Europe and the Americas is expected to reach $2.1 billion in 2026 and is seeking new technologies to meet a rapidly growing demand
• SuperCom’s innovative solutions promise a critical technological and social impact – improving public safety worldwide and reducing governmental costs in the process
• The company’s growth strategy includes potential acquisitions and expansion into new regions with limited electronic monitoring capabilities

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity security solutions offering advanced safety, identification, and security products and solutions to governments, introduces its all-in-one PureOne monitoring device. This device features three built-in modules – the BLE module allows the device to communicate with the Pure Beacon (home unit) Bluetooth device, the GNSS module for location positioning, and the LTE cellular module for communication with the company’s Pure Monitor. The device has a portable charger, and both components feature an LED interface for easier system navigation.

Since 1988, SuperCom has been a trusted global provider of traditional and digital identity offerings with a mission to revolutionize the public safety sector through proprietary electronic monitoring technology, data intelligence, and complementary services. The company’s largest focus is on the electronic monitoring of offenders and domestic violence prevention.

In alignment with its mission, the company offers an all-in-one PureSecurity offender monitoring suite, accompanied by GPS monitoring, home detention, domestic violence prevention, and more. These services are specifically catered to serve each client’s needs. The competitive advantages of SuperCom’s technology include:

• Long Battery Life (No Tag Charging Required)
• Ultra Lightweight Form Factor
• Next-Gen Location Tech
• Protection of Domestic Violence Victims

According to Berg Insight, the global electronic offender monitoring market in Europe and the Americas is expected to reach $2.1 billion in 2026. These electronic monitoring devices aim to increase offender accountability, reduce recidivism rates, and enhance public safety by providing an additional tool over traditional methods of community supervision (https://ibn.fm/DuCI5).

The world’s criminal justice systems face challenges that SuperCom can help solve. Countries are seeing high recidivism rates, prison overcrowding, excessive costs, and unsafe communities. SuperCom’s solutions help negate these challenges and offer a superior alternative for a growing social problem.

SuperCom’s solutions create a positive social impact – improving public safety worldwide. The company’s solutions help save lives and eradicate domestic violence, increase overall public safety and well-being, offer meaningful rehabilitation and proper reentry to society, and facilitate reducing incarcerated population sizes and associated governmental expenditures.

The company’s solutions are a versatile alternative to traditional methods. It offers capabilities allowing governments to provide a wide array of at-home programs, including house arrest, GPS monitoring, domestic violence support, inmate monitoring, alcohol monitoring, and other rehabilitation services. SuperCom has already won over 50 new multi-year governmental projects since 2018.

SuperCom’s growth strategy includes potential acquisitions and expansion into countries and states with limited electronic monitoring. In a press release about the company’s project with the government of Finland, SuperCom President and CEO Ordan Trabelsi said there was a growing number of countries opting for advanced electronic monitoring solutions, which highlights the increasing need for exceptional technology in this industry. “We take pride in the fact that our innovative and proven technology is chosen repeatedly, allowing us to continue revolutionizing the electronic monitoring industry as we enter new European countries,” Trabelsi added (https://ibn.fm/LSdhh).

SuperCom continues solidifying its position as a leading electronic monitoring market and a trusted partner to governments worldwide – providing innovative and proven technology and services to help governments improve public safety, reduce recidivism, and lower overall costs.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• RVL Pharmaceuticals’ CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year’s H.C. Wainwright Annual Global Investment Conference in New York City
• The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis
• RVL Pharmaceuticals plans to continue marketing to medical aesthetics providers and will launch a direct-to-consumer campaign later this year
• The medical aesthetics market was valued at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company, recently announced that its CEO Brian Markison will be participating in a fireside chat and hosting 1-on-1 investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Tuesday, September 12, 2023. Mr. Markison will be discussing the company and its commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, also known as ptosis or low-lying eyelid(s), in adults (https://ibn.fm/097y6).

UPNEEQ(R) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (“FDA”) for acquired blepharoptosis. The company obtained the necessary FDA approvals in July 2020 – launching UPNEEQ(R) in September 2020 to a limited number of eye care professionals. The company began expanding its commercial operations in 2021 to include ophthalmology, optometry, and oculoplastic specialties. In 2022, UPNEEQ(R) was launched into the U.S. medical aesthetics market.

In 2022, the global medical aesthetics market had an estimated value of $13.9 billion. By 2027, the estimated value is expected to reach $23.4 billion, representing a compound annual growth rate (“CAGR”) of 11%. The market’s projected growth is attributed to the rising preference for minimally invasive aesthetic procedures over traditional surgical options (https://ibn.fm/Ny5DV).

UPNEEQ(R), the first and only FDA-approved eye drop for low-lying eyelids, fits into the non-invasive medical aesthetics category. With a single drop per day, clinical trials showed an average of one-millimeter lift to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit. Testing also showed that UPNEEQ(R) was well tolerated by participants and is safe; side effects were similar to those experienced in the placebo group.

RVL Pharmaceuticals believes that the growth in the medical aesthetics and eye care markets will be driven by an aging population and an increased life expectancy, resulting in more consumers who desire improved appearance and well-being over a longer period. The company also anticipates other contributing factors that include the growing awareness, utilization, and improved accessibility of treatments due to an increase in physicians offering eye care and medical aesthetics services.

Low-lying lids can affect adults of all ages. A survey conducted by eye care providers and medical aesthetics specialists revealed they believe that approximately half of the adult patients visiting their practices are affected by drooping or low-lying eyelids. RVL Pharmaceuticals estimates that approximately 60% of adult women self-identify as having some degree of ptosis, indicating that they are bothered by the position of their eyelids.

UPNEEQ(R) customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and a broad range of practitioners qualified to diagnose and treat acquired blepharoptosis in adults. Patients can purchase UPNEEQ(R) directly from eye care, medical aesthetic professionals, or RVL Pharmaceuticals’ wholly owned pharmacy, RVL Pharmacy LLC. To support patients, RVL Pharmaceuticals launched the Elevate platform this year, which enables UPNEEQ(R) orders and subscription refills across HCP practices and RVL Pharmacy patients.

RVL Pharmaceuticals’ near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. RVL is focused on raising patient and provider awareness of acquired ptosis through medical conferences, HCP and direct-to-consumer advertising, social media, and marketing partnerships.

The company’s fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference will be webcast and available live and via replay from the RVL Pharmaceuticals website under the Investors & News section. The playback will be accessible for up to 90 days after the conference’s conclusion.

For more information, visit the company’s website at www.RVLPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP

• XESP continues to affirm its commitment to optimizing companies’ growth, mainly through its managed service that offers digital activation and engagement solutions
• Its proprietary technology, the Digital Engagement Engine(TM), which utilizes automation, unique data management, and a modern workflow, has proven to offer what no other competitor offers in the market
• This product is founded on critical principles integral to building customer loyalty, among them the importance of meeting customers’ demands for the modern digital experience
• Through this proprietary technology, XESP offers a solution that makes addressing the changing consumer demands a lot easier, faster, and more efficient

Electronic Servitor Publication Network (OTCQB: XESP), is a digital engagement company and a market disruptor offering cutting-edge data analysis and intelligent technology to help enterprises reach their target markets. Through its managed service, which offers digital activation and engagement solutions, the company looks to provide superior intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, all tested avenues for elevating customer experiences and response.

XESP is focused on the use of evolving technologies to increase customer reach and spur organizational growth. The company’s proprietary technology, the Digital Engagement Engine(TM), is an example of the company’s focus on solutions that directly address clients’ digital engagement needs.

By utilizing a combination of automation, unique data management, and a modern workflow built on a microservices architecture, XESP can offer what no competitor offers in the market. The company has differentiated itself through this technology, offering a unique value proposition.

“The Digital Engagement Engine(TM) isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.”

A recent Destination CRM article written by Trey Simonton of MadCap Software points to 4 ways for building customer loyalty (https://ibn.fm/VvNRK):

1. Meet customers’ demands for modern digital experiences
2. Leverage online guides to upsell related offerings
3. Use online tutorials and guides to attract new customers
4. Support growing customer calls for sustainability

XESP’s offering is founded on such basic principles, serving as the building blocks for the managed services the company provides and how it tailors its Digital Engagement Engine specifically to the needs of the intended customer.

For starters, for a business to build customer loyalty, it must more effectively meet customer demands, specifically for the modern digital experience that defines the industry today. With more sales being conducted online, digital experiences can no longer be ignored. In 2022, over 21% of global retail sales were all conducted online. This amounted to $5.7 trillion, with 2.14 billion people shopping online in 2020 (https://ibn.fm/n71pq). Meeting these people’s demands for the modern digital experience makes a massive difference between a successful and failed business today.

Another principle is leveraging online guides to upsell related offerings. With more customers today preferring self-service over calling a support center, more businesses are moving toward enabling this functionality, although live personal interactions can be kept as one of the options. XESP, through its technology, is helping to refine the process, offering innovative solutions that present offers for related products tailored to specific customers, their purchase history, and overall preferences.

This of course also complements the growing customer calls for sustainability, with 79% of consumers pushing for brands to focus on developing working practices that consider the environment.

As consumer demands continue to evolve, especially in this digital age, more businesses are learning the importance of the internet and are being forced to cater to the changing consumer demands. XESP, through its proprietary technology, offers a solution that makes the entire process easier, faster, and more efficient, with a guarantee of elevating customer experiences. By offering meaningful customer interactions, businesses can realize growth, higher customer retention, and customer satisfaction in the long run.

“That meaningful interaction drives a greater relationship with your audience and trust,” noted Peter Hager, XESP’s CEO. “Ultimately, it drives greater growth in your organization and, very simply put, replicates what you do face-to-face. And if we can do that online, which the Digital Engagement Engine helps you do, you’re going to produce better results,” he added (https://ibn.fm/1501i).

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• In July 2023, LSDI launched Twilight, a new sleep aid product
• The company in July 2023 announced its acquisition of SANA-013 from Wesana Health; SANA-013 is being developed for the treatment of several mental health and central nervous system conditions
• LSDI in May 2023 launched its new Mindful product line designed to enhance well-being and promote a mindful approach to life
• Also in May 2023, the company announced a partnership with non-profit TheraPsil to advance medical psilocybin access and research
• LSDI announced in April 2023 that its board had approved the repurchase of up to 500,000 shares of its Class A common stock

Lucy Scientific Discovery (NASDAQ: LSDI) is an early-stage psychotropics manufacturing company focused on becoming the premier contract research, development and manufacturing organization for the emerging psychotropics-based medicines industry.

The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. Lucy Scientific Discovery and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada).

The company’s mission is to make its products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs, including various mental health and addiction disorders. LSDI targets customers that include an increasing number of the leading universities, hospitals and other public, private and government institutions throughout the world that have launched research programs aimed at understanding the therapeutic potential of a range of psychedelic substances.

The company is headquartered in Victoria, British Columbia, Canada.

Products

LSDI produces a variety of high-quality natural, synthetic and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market. The company believes the emerging psychotropics industry will pave the way to a brighter future in mental health and overall wellness. LSDI is dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies.

In Canada, the psychedelic compounds that LSDI is approved to produce under its Dealer’s License are regulated under the Controlled Drugs and Substances Act, or CDSA. Those compounds include:

• Psilocybin
• Psilocin
• Lysergic acid diethylamide, or LSD
• N,N-Dimethyltryptamine, or N,N-DMT
• 3,4-Methylenedioxymethamphetamine, or MDMA
• 4-Bromo-2,5-Dimethoxybenzeneethanamine, or 2C-B

The company also sells its consumer psychotropic products directly online and through retailers. Those products, described as microdose mushroom formulations, include a sleep aid, Twilight, and a mindfulness enhancer, Mindful.

Market Opportunity

According to a report from Global Market Insights, the psychotropics drug market had an estimated value of $20.2 billion in 2022 and is projected to reach a value of nearly $37.6 billion by 2032. That represents a CAGR of 6.4% for the forecast period. Factors driving market growth include the increasing prevalence of mental disorders, technological advancements in drug development, a rising geriatric population and increasing healthcare expenditures, the report states.

A growing awareness of mental health issues and an effort to reduce the stigma surrounding psychiatric disorders have encouraged more individuals to seek help, which in turn boosts the market. In addition, advancements in neuroscience, pharmacology and drug development have led to the discovery of new and more effective central nervous system therapeutics.

Innovative treatments offering better outcomes with fewer side effects attract patients and healthcare providers, also driving market growth.

Management Team

LSDI’s executive team brings deep experience in the development and commercialization of products featuring controlled substances, as well as the navigation of regulatory structures applicable to these products.

Richard Nanula is Chairman and CEO of LSDI. He has more than 35 years of leadership experience at several of the largest companies in the world, having been a senior executive at The Walt Disney Company, Amgen, Colony Capital and Starwood Hotels and Resorts. He has also served as a board member for Boeing Corporation and Starwood Capital, where he provided corporate guidance and oversight. He holds an MBA from Harvard Business School.

Assad J. Kazeminy, Ph.D., is Chief Scientific Officer at LSDI. He previously served as CEO of Irvine Pharmaceutical Services Inc. and Avrio Biopharmaceutical LLC, and he has founded several drug development companies. He has over 30 years of research and development experience in the biopharmaceutical industry. He received his Ph.D. in Pharmaceutical Science and Biochemistry from Esfahan University in Iran. He completed a Post Doctorate course of study at the University of Southern California Medical School, Department of Pharmacology.

Brian Zasitko, CPA, CA, is the company’s CFO. He is a Director of Invictus Accounting Group LLP, a professional services firm providing finance, advisory and accounting services. He also serves as CFO of Lobe Sciences Ltd., a company developing psychedelic compounds as therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. He has an undergraduate degree from Simon Fraser University and a CPA (“CA”) from Certified Professional Accountants, British Columbia.

For more information, visit the company’s website at www.LucyScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://ibn.fm/LSDI

• CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin
• The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM
• 151 patients have been enrolled in the study, marking the data cutoff point and a significant milestone toward reporting topline results before the end of the year
• Based on the results seen preclinically, the company remains optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”), and neuro-oncology, recently announced the presentation of updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. Most notably, this novel anthracycline demonstrated its capability to be a safe and innovative potential treatment option for GBM, having shown aspects integral to effective therapy for the disease (https://ibn.fm/yp5AC).

“Berubicin has demonstrated its capability to be an innovative treatment in GBM that is safe and well tolerated, which has the potential to be a novel and effective therapy for this disease,” noted Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals.

So far, 151 patients have been enrolled in the clinical study, with 105 set on Berubicin while the remaining 46 will be on Lomustine. This marks the data cutoff point for CNS Pharmaceuticals, a significant milestone toward reporting topline results before the end of the year.

“We are approaching the most important milestone to date since we launched CNS Pharma,” noted John Climaco, CNS Pharmaceuticals’ CEO.

“We are just a few months away from reporting topline results from our Berubicin potentially pivotal study interim analysis and, although we do not know what the data looks like at this time, we remain hopeful as we also approach full enrollment of the trial,” he added (https://ibn.fm/0Yy0n).

The primary endpoint of this study is Overall Survival (“OS”), a goal that the United States Food and Drug Administration (“FDA”) has recognized as the basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. Approximately 50% of patients on both arms have completed the study, with each showing comparable demographics, including age, race, gender, KPS, and BSA. Based on the results seen preclinically and in the clinical study thus far, the company remains optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients.

“Based on the results we’ve seen preclinically and in the clinic thus far, including these updated results from our ongoing potentially pivotal study, we remain optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients,” noted Dr. Silberman.

The FDA has already granted CNS Pharmaceuticals Fast Track Designation for Berubicin, allowing it more frequent interactions with the agency, both for guidance and review. In addition, the company has received Orphan Drug Designation from the FDA, affording it seven years of marketing exclusivity upon approval of an NDA. Progress from its ongoing study is inching closer to enjoying these benefits and more, and its management is optimistic that it will offer a more viable treatment option for GBM than what is already in the market.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP